Get the Stockscreener App
13.49
5.86%
-0.84
After Hours:
13.40
-0.09
-0.67%
Novocure Ltd stock is traded at $13.49, with a volume of 1.18M.
It is down -5.86% in the last 24 hours and up +10.48% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$14.33
Open:
$14.35
24h Volume:
1.18M
Relative Volume:
0.69
Market Cap:
$1.51B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-9.6357
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-7.98%
1M Performance:
+10.48%
6M Performance:
-16.11%
1Y Performance:
-9.28%
1-Day Range:
$13.24
$14.45
1-Week Range:
$13.24
$14.77
52-Week Range:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.49 | 1.60B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone - simplywall.st
Using data tools to time your NovoCure Limited exitJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
NovoCure's (NVCR) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR) - simplywall.st
Should I buy NovoCure Limited (038) stock before earnings seasonJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why NovoCure Limited (038) stock remains top ratedEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Analysts - Defense World
Published on: 2025-10-05 04:02:03 - newser.com
Analyzing NovoCure Limited with multi timeframe chartsQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled - simplywall.st
Volume spikes in NovoCure Limited stock – what they mean2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will NovoCure Limited (038) stock keep high P E multiplesRecession Risk & Safe Entry Trade Signal Reports - newser.com
Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases - simplywall.st
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Medical Technology Firm Novocure Schedules Q3 2025 Financial Results with Investor Conference Call - Stock Titan
Novocure to Report Third Quarter 2025 Financial Results - The Globe and Mail
Why NovoCure Limited is moving todayQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com Nigeria
NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Pattern recognition hints at NovoCure Limited upsideTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Novocure (NVCR) Announces Positive Phase 3 METIS Trial Results - GuruFocus
Novocure’s cancer therapy delays brain metastases progression By Investing.com - Investing.com Australia
Novocure’s cancer therapy delays brain metastases progression - Investing.com India
15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan
Live market analysis of NovoCure LimitedJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why NovoCure Limited stock is rated strong buyJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
Washington Capital Management Inc. Invests $374,000 in NovoCure Limited $NVCR - MarketBeat
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - Ariva
How NovoCure Limited stock benefits from strong dollarJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Regression analysis insights on NovoCure Limited performancePortfolio Risk Report & Fast Gain Swing Alerts - newser.com
Published on: 2025-09-28 23:33:37 - newser.com
NovoCure Limited stock outlook for YEARJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Is NovoCure Limited (038) stock a buy on weaknessJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
42,600 Shares in NovoCure Limited $NVCR Purchased by Strs Ohio - MarketBeat
How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer - simplywall.st
NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy - simplywall.st
Using Ichimoku Cloud for NovoCure Limited technicalsTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
NovoCure Limited $NVCR Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
Multi factor analysis applied to NovoCure LimitedDip Buying & Stepwise Trade Signal Implementation - newser.com
Rally Mode: What is the long term forecast for NovoCure Limited stock2025 Price Targets & Low Drawdown Momentum Ideas - خودرو بانک
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
1.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):